SCHEDULE: Avoro Capital Advisors Discloses 5.4% Stake in Soleno
Beneficial Ownership Report
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a 5.4% beneficial ownership stake in Soleno Therapeutics Inc., holding 2.9 million shares for investment purposes.
Summary
- Avoro Capital Advisors LLC and Behzad Aghazadeh collectively reported beneficial ownership of 2,900,000 shares of Soleno Therapeutics Inc. Common Stock.
- This represents a 5.4% stake in the company, calculated based on 53,710,025 shares outstanding as of October 31, 2025.
- The shares were acquired and are held for investment purposes in the ordinary course of business, not with the intent to change or influence control of the issuer.
- Avoro Capital Advisors LLC is a Delaware limited liability company providing investment advisory and management services.
- Behzad Aghazadeh is identified as the portfolio manager and controlling person of Avoro Capital Advisors LLC.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, as a notable institutional investor has disclosed a significant stake, suggesting a vote of confidence in Soleno Therapeutics' future prospects.
Positives
- A significant institutional investor, Avoro Capital Advisors, and its controlling person, Behzad Aghazadeh, have taken a 5.4% stake in Soleno Therapeutics, indicating confidence in the company's prospects.
- The investment is stated to be for ordinary course investment purposes, suggesting a long-term, passive interest rather than an activist stance.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that a significant stake by an investment advisor like Avoro Capital Advisors in a biotechnology company such as Soleno Therapeutics often signals a belief in the company's long-term potential, particularly concerning its drug pipeline or market position. Such filings are closely watched by the market for signs of institutional interest.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further institutional interest, positively impacting share price.
Key Dates
| Date | Description |
|---|---|
| 2025-10-31 | Date as of which 53,710,025 shares of Common Stock were outstanding, as reported in the Company's Form 10-Q. |
| 2025-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2026-02-17 | Filing date of the Schedule 13G by Avoro Capital Advisors LLC and Behzad Aghazadeh. |
Recommendation
holdThe disclosure of a 5.4% beneficial ownership by Avoro Capital Advisors and Behzad Aghazadeh is a positive indicator of institutional confidence in Soleno Therapeutics. However, this filing primarily reports ownership and does not provide new fundamental data on the company's operations or financial performance. Investors should 'hold' and monitor for further developments, using this as a signal to conduct deeper due diligence into Soleno's prospects rather than an immediate buy trigger.
Keywords
Soleno Therapeutics, Avoro Capital Advisors, Behzad Aghazadeh, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.